L-Arginine Supplements in Treating Women Who Are Cancer Survivors

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Wake Forest Cancer Center CCOP Research Base
ClinicalTrials.gov Identifier:
NCT00459134
First received: April 9, 2007
Last updated: March 15, 2013
Last verified: March 2013
  Purpose

RATIONALE: L-arginine supplements may improve the quality of life and sexual function in women who are cancer survivors.

PURPOSE: This randomized clinical trial is studying an L-arginine supplement to see how well it works compared with a placebo in treating women who are cancer survivors.


Condition Intervention
Sexual Dysfunction
Sexuality and Reproductive Issues
Unspecified Adult Solid Tumor, Protocol Specific
Dietary Supplement: ArginMax
Dietary Supplement: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: A Randomized Study to Determine Whether ArginMax Improves the Sexual Function and Quality of Life in Female Cancer Survivors

Resource links provided by NLM:


Further study details as provided by Wake Forest Cancer Center CCOP Research Base:

Primary Outcome Measures:
  • Determine whether ArginMax improves the quality of life and sexual function. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Determine whether ArginMax improves the quality of life and sexual function for women cancer survivors by using the FACT-G and FSFI instruments.


Secondary Outcome Measures:
  • Quality of life [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    • Assess differences in quality of life between the two groups.
    • Determine differences in toxicity between the two groups.
    • Describe the sexual function symptom clusters (if any) in women cancer survivors.
    • To assess the effect of race on sexual function and quality of life.


Enrollment: 186
Study Start Date: May 2007
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I: ArginMax
ArginMax® (including placebo)
Dietary Supplement: ArginMax
Given orally
Other Name: L-arginine
Placebo Comparator: Arm II
Patients receive oral placebo twice daily
Dietary Supplement: placebo
Given orally

Detailed Description:

OBJECTIVES:

Primary

  • Determine whether an L-arginine-based nutritional supplement (ArginMax®) improves the quality of life and sexual function in female cancer survivors.

Secondary

  • Compare quality of life of patients treated with ArginMax® vs placebo.
  • Compare toxicity of these regimens in these patients.
  • Describe the sexual function symptom clusters (if any) in these patients.

OUTLINE: This is a randomized, double-blind, parallel-group, placebo-controlled, multicenter study. Patients are stratified according to ECOG performance status (0 or 1 vs 2 or 3), type of malignancy (pelvic vs nonpelvic), and ovarian functional status (yes vs no). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive an oral L-arginine-based nutritional supplement (ArginMax®) twice daily.
  • Arm II: Patients receive oral placebo twice daily. In both arms, treatment continues for 12 weeks in the absence of unacceptable toxicity.

Sexual function, quality of life, and toxicity are assessed at baseline and every 4 weeks for 12 weeks.

PROJECTED ACCRUAL: A total of 186 patients will be accrued for this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA:

Any female cancer survivor who identifies herself as concerned with her sexual quality of life and answering yes to all three of the screening questions.

  • Must express interest in sexual activity
  • At least 6 months following completion of all cancer therapy. Hormonal therapy and treatment with Herceptin are allowed.
  • No evidence of active cancer based on physical exam and/or radiographic images obtained within 3 months of study.
  • Absence of any mental, medical or physical disorder know to affect sexual function.
  • No participation in another study with an investigational study drug or device during the 30 days prior to start of study drug.
  • Lab values must meet the following criteria at study entry: WBC ≥ 2000, Hgb ≥ 10gm/dl, creatinine ≤ 1.5 x ULN, plt ≥ 100,000, T Bili ≤ 1.5
  • ECOG performance status must be 0-2.
  • Must be able to take oral medication
  • Must be 18 years old or older
  • Must be minority (non-white) female.

EXCLUSION CRITERIA:

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ArginMax.
  • Currently taking any blood thinner such as aspirin (one 81mg aspirin, or one baby aspirin per day allowed), Persantine, Heparin, Lovenox, or Coumadin (low dose Coumadin for catheter patency is allowed).
  • Patients currently taking Ginkgo Biloba are not allowed on this study.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac, arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements and/or ability for sexual function.
  • Pregnant women are excluded from this study because ArginMax may be an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ArginMax, breastfeeding should be discontinued if the mother is treated with ArginMax.
  • Because patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy, HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with ArginMax. Appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated.
  • Any planned surgery during study participation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00459134

  Hide Study Locations
Locations
United States, Delaware
CCOP - Christiana Care Health Services
Newark, Delaware, United States, 19713
United States, Florida
CCOP - Mount Sinai Medical Center
Miami Beach, Florida, United States, 33140
United States, Georgia
MBCCOP - Medical College of Georgia Cancer Center
Augusta, Georgia, United States, 30912-4000
United States, Illinois
MBCCOP - JHS Hospital of Cook County
Chicago, Illinois, United States, 60612
CCOP - Central Illinois
Decatur, Illinois, United States, 62526
United States, Indiana
CCOP - Northern Indiana CR Consortium
South Bend, Indiana, United States, 46601
United States, Iowa
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, United States, 52403-1206
United States, Louisiana
MBCCOP - LSU Health Sciences Center
New Orleans, Louisiana, United States, 70112
Feist-Weiller Cancer Center at Louisiana State University Health Sciences
Shreveport, Louisiana, United States, 71130-3932
United States, Michigan
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, United States, 48106
CCOP - Beaumont
Royal Oak, Michigan, United States, 48073-6769
United States, Missouri
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, United States, 65804
CCOP - Heartland Research Consortium
St. Louis, Missouri, United States, 63131
CCOP - St. Louis-Cape Girardeau
St. Louis, Missouri, United States, 63141
United States, New York
Hematology Oncology Associates of Central New York, PC - Northeast Center
East Syracuse, New York, United States, 13057
CCOP - North Shore University Hospital
Manhassett, New York, United States, 11030
United States, North Carolina
Alamance Cancer Center at Alamance Regional Medical Center
Burlington, North Carolina, United States, 27216
Hugh Chatham Memorial Hospital
Elkin, North Carolina, United States, 28621
Southeastern Medical Oncology Center - Goldsboro
Goldsboro, North Carolina, United States, 27534
Caldwell Memorial Hospital
Lenoir, North Carolina, United States, 28645
Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States, 27157-1096
United States, Ohio
CCOP - Columbus
Columbus, Ohio, United States, 43215
United States, Pennsylvania
CCOP - Main Line Health
Wynnewood, Pennsylvania, United States, 19096
United States, South Carolina
CCOP - Upstate Carolina
Spartanburg, South Carolina, United States, 29303
United States, South Dakota
CCOP - Sioux Community Cancer Consortium
Sioux Falls, South Dakota, United States, 57104
Sponsors and Collaborators
Wake Forest Cancer Center CCOP Research Base
Investigators
Principal Investigator: Kathryn M. Greven, MD Wake Forest Cancer Center CCOP Research Base
  More Information

Additional Information:
No publications provided

Responsible Party: Wake Forest Cancer Center CCOP Research Base
ClinicalTrials.gov Identifier: NCT00459134     History of Changes
Other Study ID Numbers: CCCWFU 97106, U10CA081851
Study First Received: April 9, 2007
Last Updated: March 15, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Wake Forest Cancer Center CCOP Research Base:
sexual dysfunction
sexuality and reproductive issues
unspecified adult solid tumor, protocol specific

ClinicalTrials.gov processed this record on August 28, 2014